LOS ANGELES, Nov. 8, 2008 (GLOBE NEWSWIRE) -- Khang & Khang LLP today announced it is investigating potential claims against AtriCure, Inc. ("AtriCure" or the "Company") (Nasdaq:ATRC) concerning possible securities violations arising from public statements made by the Company between May 10, 2007 and October 31, 2008. On October 31, 2008 the Company revealed that the U.S. Department of Justice-Civil Division (the "DOJ") is investigating AtriCure's marketing practices utilized in connection with AtriCure's surgical ablation system to treat atrial fibrillation, a specific use outside the Federal Food and Drug Administration's 510(k) clearance, and investigating whether AtriCure instructed hospitals to bill Medicare for surgical ablation using incorrect billing codes.
If you purchased AtriCure common stock between May 10, 2007 and October 31, 2008 and would like to learn more about these claims or have information about these claims, or if you have any questions concerning this Notice, wish to discuss these matters, or have any questions with regard to your rights or interests with respect to these matters, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, at 1901 Avenue of the Stars, 2nd Floor, Los Angeles, California 90067, or by telephone at (310) 461-1342, or by email to Joon@Khanglaw.com.